Optimizing medication management for patients with cirrhosis: Evidence‐based strategies and their outcomes
dc.contributor.author | Thomson, Mary J. | |
dc.contributor.author | Lok, Anna S. | |
dc.contributor.author | Tapper, Elliot B. | |
dc.date.accessioned | 2018-11-20T15:35:17Z | |
dc.date.available | 2020-01-06T16:40:59Z | en |
dc.date.issued | 2018-11 | |
dc.identifier.citation | Thomson, Mary J.; Lok, Anna S.; Tapper, Elliot B. (2018). "Optimizing medication management for patients with cirrhosis: Evidence‐based strategies and their outcomes." Liver International 38(11): 1882-1890. | |
dc.identifier.issn | 1478-3223 | |
dc.identifier.issn | 1478-3231 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/146454 | |
dc.description.abstract | Cirrhosis is a morbid condition associated with frequent hospitalizations and high mortality. Management of cirrhosis requires complex medication regimens to treat underlying liver disease, complications of cirrhosis and comorbid conditions. This review examines the complexities of medication management in cirrhosis, barriers to optimal medication use, and potential interventions to streamline medication regimens and avoid medication errors. A literature review was performed by searching PUBMED through December 2017 and article reference lists to identify articles relevant to medication management, complications, adherence, and interventions to improve medication use in cirrhosis. The structural barriers in cirrhosis include sheer medication complexity related to the number of medications and potential for cognitive impairment in this population, faulty medication reconciliation and limited adherence. Tested interventions have included patient self‐education, provider driven patient education, intensive case management including medication blister packs and smartphone applications. Initiatives are needed to improve patient, caregiver and provider education on appropriate use of medications in patients with cirrhosis. A multidisciplinary team should be established to coordinate care with close monitoring, address patient and caregiver concerns, and to provide timely access to outpatient evaluation of urgent/complex issues. Future studies evaluating the clinical outcomes and cost effectiveness of interventions are needed. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | patient education | |
dc.subject.other | medication adherence | |
dc.subject.other | end‐stage liver disease | |
dc.subject.other | case management | |
dc.title | Optimizing medication management for patients with cirrhosis: Evidence‐based strategies and their outcomes | |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/146454/1/liv13892_am.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/146454/2/liv13892.pdf | |
dc.identifier.doi | 10.1111/liv.13892 | |
dc.identifier.source | Liver International | |
dc.identifier.citedreference | Kanwal F, Asch SM, Kramer JR, Cao Y, Asrani S, El‐Serag HB. Early outpatient follow‐up and 30‐day outcomes in patients hospitalized with cirrhosis. Hepatology. 2016; 64: 569 ‐ 581. | |
dc.identifier.citedreference | Kalaitzakis E, Björnsson E. Inadequate use of proton‐pump inhibitors in patients with liver cirrhosis. Eur J Gastro Hepatol. 2008; 20: 512 ‐ 518. | |
dc.identifier.citedreference | Ge PS, Runyon BA. The changing role of beta‐blocker therapy in patients with cirrhosis. J Hepatol. 2014; 60: 643 ‐ 653. | |
dc.identifier.citedreference | Larrey D, Salse A, Ribard D, et al. Education by a nurse increases response of patients with chronic hepatitis C to therapy with peginterferon‐alpha2a and ribavirin. Clin Gastroenterol Hepatol. 2011; 9: 781 ‐ 785. | |
dc.identifier.citedreference | Volk ML, Fisher N, Fontana RJ. Patient knowledge about disease self‐management in cirrhosis. Am J Gastroenterol. 2013; 108: 302 ‐ 305. | |
dc.identifier.citedreference | Wigg AJ, McCormick R, Wundke R, Woodman RJ. Efficacy of a chronic disease management model for patients with chronic liver failure. Clin Gastroenterol Hepatol. 2013; 11: 850 ‐ 858, e851–854. | |
dc.identifier.citedreference | Coté GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep. 2008; 10: 208 ‐ 214. | |
dc.identifier.citedreference | Bajaj JS, Thacker LR, Heuman DM, et al. The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology. 2013; 58: 1122 ‐ 1132. | |
dc.identifier.citedreference | Ganapathy D, Acharya C, Lachar J, et al. The patient buddy app can potentially prevent hepatic encephalopathy‐related readmissions. Liv Int. 2017; 37: 1843 ‐ 1851. | |
dc.identifier.citedreference | Zwar N, Harris M, Griffiths R, et al. A systematic review of chronic disease management. 2017. | |
dc.identifier.citedreference | Mellinger JL, Volk ML. Multidisciplinary management of patients with cirrhosis: a need for care coordination. Clin Gastroenterol Hepatol. 2013; 11: 217 ‐ 223. | |
dc.identifier.citedreference | Kanwal F, Volk M, Singal A, Angeli P, Talwalkar J. Improving quality of health care for patients with cirrhosis. Gastroenterology. 2014; 147: 1204 ‐ 1207. | |
dc.identifier.citedreference | Hayward KL, Martin JH, Cottrell WN, et al. Patient‐oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial. Trials. 2017; 18: 339. | |
dc.identifier.citedreference | Tapper EB, Bonder A, Cardenas A. Preventing and treating acute kidney injury among hospitalized patients with cirrhosis and ascites: a narrative review. Am J Med. 2016; 129: 461 ‐ 467. | |
dc.identifier.citedreference | Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Paper presented at: Mayo Clinic Proceedings. 2010. | |
dc.identifier.citedreference | Bajaj JS, Thacker LR, Heuman DM, et al. Cognitive performance as a predictor of hepatic encephalopathy in pretransplant patients with cirrhosis receiving psychoactive medications: a prospective study. Liver Transpl. 2012; 18: 1179 ‐ 1187. | |
dc.identifier.citedreference | Tapper EB, Risech‐Neyman Y, Sengupta N. Psychoactive medications increase the risk of falls and fall‐related injuries in hospitalized patients with cirrhosis. Clin Gastroenterol Hepatol. 2015; 13: 1670 ‐ 1675. | |
dc.identifier.citedreference | Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol. 2006; 97: S77 ‐ S81. | |
dc.identifier.citedreference | Kamal S, Khan MA, Seth A, et al. Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta‐analysis. Am J Gastroenterol. 2017; 112: 1495 ‐ 1505. | |
dc.identifier.citedreference | Serper M, Patzer RE, Reese PP, et al. Medication misuse, nonadherence, and clinical outcomes among liver transplant recipients. Liver Transpl. 2015; 21: 22 ‐ 28. | |
dc.identifier.citedreference | Asavakarn S, Sirivatanauksorn Y, Promraj R, et al. Systematic pharmaceutical educational approach to enhance drug adherence in liver transplant recipients. Transpl Proc. 2016; 48: 1202 ‐ 1207. | |
dc.identifier.citedreference | Promraj R, Dumronggittigule W, Sirivatanauksorn Y, et al. Immunosuppressive medication adherence in liver transplant recipients. Transpl Proc. 2016; 48: 1198 ‐ 1201. | |
dc.identifier.citedreference | Russo MW, Levi DM, Pierce R, et al. A prospective study of a protocol that reduces readmission after liver transplantation. Liver Transpl. 2016; 22: 765 ‐ 772. | |
dc.identifier.citedreference | Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010; 59: 105 ‐ 110. | |
dc.identifier.citedreference | Scaglione S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the United States: a population‐based study. J Clin Gastroenterol. 2015; 49: 690 ‐ 696. | |
dc.identifier.citedreference | Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2017; 67: 123 ‐ 133. | |
dc.identifier.citedreference | Wong R, Liu B, Bhuket T. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross‐sectional analysis of 2011–2014 National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2017; 46: 974 ‐ 980. | |
dc.identifier.citedreference | Beste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, Ioannou GN. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001–2013. Gastroenterology. 2015; 149: 1471 ‐ 1482, e1475. | |
dc.identifier.citedreference | Murphy SL, Kochanek KD, Xu J. Deaths: final data for 2012. Natl Vital Stat Rep. 2015; 63: 1 ‐ 117. | |
dc.identifier.citedreference | Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012; 143: 1179 ‐ 1187, e1173. | |
dc.identifier.citedreference | Hudson B, Round J, Georgeson B, et al. Cirrhosis with ascites in the last year of life: a nationwide analysis of factors shaping costs, health‐care use, and place of death in England. Lancet Gastroenterol Hepatol. 2018; 3: 95 ‐ 103. | |
dc.identifier.citedreference | Tapper EB, Halbert B, Mellinger J. Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate population‐based cohort study. Clin Gastroenterol Hepatol. 2016; 14: 1181 ‐ 1188, e1182. | |
dc.identifier.citedreference | Ginés P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987; 7: 122 ‐ 128. | |
dc.identifier.citedreference | Bajaj JS, Reddy KR, Tandon P, et al. The three‐month readmission rate remains unacceptably high in a large North american cohort of cirrhotic patients. Hepatology 2015; 64: 200 ‐ 208. | |
dc.identifier.citedreference | Romero‐Gomez M, Boza F, Garcia‐Valdecasas MS, Garcia E, Aguilar‐Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001; 96: 2718 ‐ 2723. | |
dc.identifier.citedreference | Wijdicks EF. Hepatic encephalopathy. N Engl J Med. 2016; 375: 1660 ‐ 1670. | |
dc.identifier.citedreference | Kuo SZ, Haftek M, Lai JC. Factors associated with medication non‐adherence in patients with end‐stage liver disease. Dig Dis Sci. 2017; 62: 543 ‐ 549. | |
dc.identifier.citedreference | Tapper EB, Finkelstein D, Mittleman MA, Piatkowski G, Chang M, Lai M. A quality improvement initiative reduces 30‐day rate of readmission for patients with cirrhosis. Clin Gastroenterol Hepatol. 2016; 14: 753 ‐ 759. | |
dc.identifier.citedreference | Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double‐blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013; 108: 1458 ‐ 1463. | |
dc.identifier.citedreference | Landis CS, Ghabril M, Rustgi V, et al. Prospective multicenter observational study of overt hepatic encephalopathy. Dig Dis Sci. 2016; 61: 1728 ‐ 1734. | |
dc.identifier.citedreference | Orr JG, Currie CJ, Berni E, et al. The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin‐α. Liv Int. 2016; 36: 1295 ‐ 1303. | |
dc.identifier.citedreference | Garcia‐Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017; 65: 310 ‐ 335. | |
dc.identifier.citedreference | Shukla R, Kramer J, Cao Y, et al. Risk and predictors of variceal bleeding in cirrhosis patients receiving primary prophylaxis with non‐selective beta‐blockers. Am J Gastroenterol. 2016; 111: 1778 ‐ 1787. | |
dc.identifier.citedreference | Chavez‐Tapia NC, Tellez‐Avila FI, Garcia‐Leiva J, Valdovinos MA. Use and overuse of proton pump inhibitors in cirrhotic patients. Med Sci Monit 2008; 14: CR468 ‐ CR472. | |
dc.identifier.citedreference | Trikudanathan G, Israel J, Cappa J, O’sullivan D. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients–a systematic review and meta‐analysis. Int J Clin Pract. 2011; 65: 674 ‐ 678. | |
dc.identifier.citedreference | Bajaj JS, Ananthakrishnan AN, Hafeezullah M, et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol. 2010; 105: 106. | |
dc.identifier.citedreference | Bajaj JS, Reddy KR, Tandon P, et al. The 3‐month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology. 2016; 64: 200 ‐ 208. | |
dc.identifier.citedreference | Polis S, Zang L, Mainali B, et al. Factors associated with medication adherence in patients living with cirrhosis. J Clin Nurs. 2016; 25: 204 ‐ 212. | |
dc.identifier.citedreference | Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol. 2012; 107: 247 ‐ 252. | |
dc.identifier.citedreference | Mueller SK, Sponsler KC, Kripalani S, Schnipper JL. Hospital‐based medication reconciliation practices: a systematic review. Arch Intern Med. 2012; 172: 1057 ‐ 1069. | |
dc.identifier.citedreference | Morisky DE, Ang A, Krousel‐Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008; 10: 348 ‐ 354. | |
dc.identifier.citedreference | Hayward KL, Valery PC, Cottrell WN, et al. Prevalence of medication discrepancies in patients with cirrhosis: a pilot study. BMC Gastroenterol. 2016; 16: 114. | |
dc.identifier.citedreference | Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353: 487 ‐ 497. | |
dc.identifier.citedreference | DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004; 42: 200 ‐ 209. | |
dc.identifier.citedreference | Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci. 2007; 52: 737 ‐ 741. | |
dc.identifier.citedreference | Ross JS, Chen J, Lin ZQ, et al. Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail 2010; 3: 97 ‐ 103. | |
dc.identifier.citedreference | Ruppar TM, Cooper PS, Mehr DR, Delgado JM, Dunbar‐Jacob JM. Medication adherence interventions improve heart failure mortality and readmission rates: systematic review and meta‐analysis of controlled trials. J Am Heart Assoc. 2016; 5: e002606. | |
dc.identifier.citedreference | Kotb A, Cameron C, Hsieh S, Wells G. Comparative effectiveness of different forms of telemedicine for individuals with heart failure (HF): a systematic review and network meta‐analysis. PLoS ONE. 2015; 10: e0118681. | |
dc.identifier.citedreference | Hameed A, Sauermann S, Schreier G. The impact of adherence on costs and effectiveness of telemedical patient management in heart failure. Appl Clin Inform. 2014; 5: 612 ‐ 620. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.